EDIT-103

N/A

Report date: 2024/09/29 14:59:52

Base Information

Drug NameEDIT-103

Drug Alias NameEDIT-103

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9

Mechanisms of ActionRHO gene transference

TargetsRhodopsin

Therapy Area/IndicationsRetinitis Pigmentosa

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEditas Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine Inc

Inactive CompaniesN/A

Active IndicationsRetinitis Pigmentosa

Inactive IndicationsN/A

Other Information

ATC CodeN/A